BDlenti-Parkinson's

BDlenti-Parkinson's is a preclinical-stage gene therapy candidate being developed by Shanghai BDgene Therapeutics for the treatment of Parkinson's disease. The program utilizes the company's proprietary BDlenti platform, which is a lentiviral vector-based system optimized for gene addition. While the specific transgene and molecular target have not been publicly identified, the therapy is intended to address the neurodegenerative pathology of Parkinson's disease by delivering therapeutic genetic material directly to affected areas of the brain. As of the latest reports, the program remains in the preclinical phase of development.